These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 36773729

  • 1. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
    Liu T, Tong S, Liao Q, Pan L, Cheng M, Rantanen J, Cun D, Yang M.
    Int J Pharm; 2023 Mar 25; 635():122702. PubMed ID: 36773729
    [Abstract] [Full Text] [Related]

  • 2. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW, Schneider M, Morrical BD, Imanidis G.
    J Pharm Sci; 2018 Apr 25; 107(4):984-998. PubMed ID: 29247741
    [Abstract] [Full Text] [Related]

  • 3. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X, Li J, Wen X, Ma S, An Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2024 Oct 25; 664():124609. PubMed ID: 39163928
    [Abstract] [Full Text] [Related]

  • 4. Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler.
    Li J, Ma S, He X, Sun Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2023 Jul 25; 642():123179. PubMed ID: 37364785
    [Abstract] [Full Text] [Related]

  • 5. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug 25; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 6. Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance.
    Lau M, Young PM, Traini D.
    Drug Dev Ind Pharm; 2017 Jun 25; 43(6):980-988. PubMed ID: 28122460
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties.
    Elsayed MMA, Alfagih IM, Brockbank K, Aodah AH, Ali R, Almansour K, Shalash AO.
    Int J Pharm; 2024 Apr 25; 655():123966. PubMed ID: 38452834
    [Abstract] [Full Text] [Related]

  • 10. Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate.
    Kumar V, Sethi B, Yanez E, Leung DH, Ghanwatkar YY, Cheong J, Tso J, Narang AS, Nagapudi K, Mahato RI.
    Int J Pharm; 2022 Mar 05; 615():121470. PubMed ID: 35041913
    [Abstract] [Full Text] [Related]

  • 11. Stability test of novel combined formulated dry powder inhalation system containing antibiotic: physical characterization and in vitro-in silico lung deposition results.
    Benke E, Farkas Á, Balásházy I, Szabó-Révész P, Ambrus R.
    Drug Dev Ind Pharm; 2019 Aug 05; 45(8):1369-1378. PubMed ID: 31096805
    [Abstract] [Full Text] [Related]

  • 12. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ, Chan LW, Heng PWS.
    Mol Pharm; 2018 Apr 02; 15(4):1635-1642. PubMed ID: 29490144
    [Abstract] [Full Text] [Related]

  • 13. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
    Thalberg K, Åslund S, Skogevall M, Andersson P.
    Int J Pharm; 2016 May 17; 504(1-2):27-38. PubMed ID: 26965200
    [Abstract] [Full Text] [Related]

  • 14. Recent developments in lactose blend formulations for carrier-based dry powder inhalation.
    Hebbink GA, Jaspers M, Peters HJW, Dickhoff BHJ.
    Adv Drug Deliv Rev; 2022 Oct 17; 189():114527. PubMed ID: 36070848
    [Abstract] [Full Text] [Related]

  • 15. Development and characterization of meropenem dry powder inhaler formulation for pulmonary drug delivery.
    Muneer S, Wang T, Rintoul L, Ayoko GA, Islam N, Izake EL.
    Int J Pharm; 2020 Sep 25; 587():119684. PubMed ID: 32736016
    [Abstract] [Full Text] [Related]

  • 16. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
    Yu J, Chan HK, Gengenbach T, Denman JA.
    Eur J Pharm Biopharm; 2017 Oct 25; 119():224-234. PubMed ID: 28655664
    [Abstract] [Full Text] [Related]

  • 17. Performance tuning of particle engineered mannitol in dry powder inhalation formulations.
    Hertel N, Birk G, Scherließ R.
    Int J Pharm; 2020 Aug 30; 586():119592. PubMed ID: 32622814
    [Abstract] [Full Text] [Related]

  • 18. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations.
    Guchardi R, Frei M, John E, Kaerger JS.
    Int J Pharm; 2008 Feb 04; 348(1-2):10-7. PubMed ID: 17689898
    [Abstract] [Full Text] [Related]

  • 19. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Li J, Chan HK.
    Eur J Pharm Biopharm; 2019 Sep 04; 142():543-552. PubMed ID: 31398437
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.